Zevra Therapeutics, Inc. (ZVRA) has disclosed a new risk, in the Corporate Activity and Growth category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zevra Therapeutics, Inc. may need to secure collaborations with larger pharmaceutical or biotechnology companies to advance and commercialize certain product candidates, yet it faces intense competition for suitable partners and complex, time‑consuming negotiations. Failure to obtain partnerships on acceptable terms could force Zevra to delay or scale back development and commercialization efforts, or to raise additional capital on potentially unfavorable terms, constraining its ability to generate future product revenue.
Overall, Wall Street has a Strong Buy consensus rating on ZVRA stock based on 6 Buys.
To learn more about Zevra Therapeutics, Inc.’s risk factors, click here.